Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII. Issue 12 (2nd December 2021)

• Record Type: Journal Article
• Authors: Kuter, Barbara J.; Marshall, Gary S.; Fergie, Jaime; Schmidt, Elvira; Pawaskar, Manjiri
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 12(2021)
• Page Start: 5372
• Page End: 5383
• Publication Date: 2021-12-02
• Subjects: Measles-mumps-rubella -- vaccines -- M-M-RII -- immunogenicity -- safety -- outbreaks; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.2007710
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Measles, mumps, and rubella are highly contagious diseases that caused significant global mortality and morbidity in the pre-vaccine era. Since its first approval in the United States over 40 years ago, M-M-RII has been used in >75 countries for prevention of these diseases. The vaccine has been part of immunization programs that have achieved dramatic global reductions in case numbers and mortality rates, as well as the elimination of measles and rubella in several countries and regions. This report summarizes over four decades of global safety, immunogenicity, efficacy, and effectiveness data for the vaccine. We include studies on the use of M-M-RII in different age groups, concomitant use with other routine childhood vaccines, administration via different routes, persistence of immunity, and vaccine effectiveness during outbreaks of measles and mumps. We conclude that M-M-RII is well tolerated and has shown consistently high performance during routine use in multiple countries, in randomized controlled trials with diverse designs, and in outbreak settings, including use as measles postexposure prophylaxis. Physicians, parents, and the public can continue to have a high degree of confidence in the use of M-M-RII as a vital part of global public health programs.